Crystal Nyitray, Encellin CEO

En­cellin rais­es about $10M for type 1 di­a­betes cell re­place­ment ther­a­py

En­cellin raised $9.9 mil­lion to join the bur­geon­ing type 1 di­a­betes space with its own cell re­place­ment ther­a­py and first-in-hu­man da­ta ex­pect­ed next year.

The small team at the San Fran­cis­co-based com­pa­ny em­ploys few­er than five peo­ple, who de­vel­oped what they call en­cap­su­lat­ed cell re­place­ment ther­a­py (En­CRT) — a porous de­vice that holds ca­dav­er­ic pri­ma­ry islets that can be sub­cu­ta­neous­ly in­sert­ed in a pa­tient and se­crete islets when need­ed to man­age type 1 di­a­betes. In type 1 pa­tients, the islet cells lo­cat­ed in the pan­creas are de­stroyed or dam­aged by the im­mune sys­tem and don’t make in­sulin.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.